Remicade — Sales to customers (Note 9)
Products & Services · Sales to customers (Note 9)Johnson & Johnson Remicade — Sales to customers (Note 9) increased by 4.7% to $953.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 13.6%, from $839.00M to $953.00M. Over 2 years (FY 2021 to FY 2024), Remicade — Sales to customers (Note 9) shows a downward trend with a -34.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates sustained market demand or successful pricing strategies, while a decrease often signals market share erosion due to biosimilar entry or product lifecycle maturity.
Detailed definition
This metric represents the total net revenue generated from the sale of the specific pharmaceutical product Remicade to...
Peer comparison
Comparable to revenue metrics for specific blockbuster drugs or key product lines reported by other large-cap pharmaceutical companies.
jnj_segment_remicade_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.56B | $1.78B | $1.52B | $2.64B | $1.33B | $1.29B | $1.12B | $974.00M | $922.00M | $868.00M | $786.00M | $839.00M | $716.00M | $934.00M | $910.00M | $953.00M |
| QoQ Change | — | +14.2% | -14.3% | +73.7% | -49.8% | -2.4% | -13.8% | -12.7% | -5.3% | -5.9% | -9.4% | +6.7% | -14.7% | +30.4% | -2.6% | +4.7% |
| YoY Change | — | — | — | — | -14.7% | -27.1% | -26.7% | -26.5% | -28.7% | — | -19.3% | -9.0% | — | +7.6% | +15.8% | +13.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's remicade — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported remicade — sales to customers (note 9) of $953.00M in Q3 2025.
- How has Johnson & Johnson's remicade — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's remicade — sales to customers (note 9) increased by 13.6% year-over-year, from $839.00M to $953.00M.
- What is the long-term trend for Johnson & Johnson's remicade — sales to customers (note 9)?
- Over 2 years (2021 to 2024), Johnson & Johnson's remicade — sales to customers (note 9) has grown at a -34.6% compound annual growth rate (CAGR), from $7.49B to $3.21B.
- What does remicade — sales to customers (note 9) mean?
- The total revenue earned from sales of the Remicade pharmaceutical product.